Pharma licensing agreement OXFORD, UK, January 13th, 2015

PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful license agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.

ESTEVE is a privately-held pharmaceutical and chemical group that focuses on innovation and excellence in health.  In a Phase II clinical study in post-operative pain, E-58425 demonstrated significant superior efficacy and safety compared to a standard of care.

Adrian Dawkes, Vice President, PharmaVentures Ltd. who was lead advisor to ESTEVE commented: “We are delighted to have worked with ESTEVE in partnering E-58425 which represents a great step forward in the pain sector.”

Fintan Walton, Chief Executive, PharmaVentures, Ltd added: “We continue to be recognised as a strong leader in healthcare deal making and this adds to a growing list of our recent successes”.

For the past 23 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.